Business Wire

NTT

25.7.2022 14:02:12 CEST | Business Wire | Press release

Share
NTT to Study Hydrogen Transportation Through Existing Pipelines

NTT Anode Energy Corporation (President and CEO: Teruyuki Kishimoto, Head Office: Minato-ku, Tokyo, NTT Anode Energy) announced a joint research and development project to study safety measures for the mass transportation of hydrogen through existing pipeline infrastructure. The study, being performed in collaboration with the National Institute of Advanced Industrial Science and Technology (President: Kazuhiko Ishimura, Chiyoda-ku, Tokyo AIST) and Toyota Tsusho Co., Ltd. (Representative Director: Ichiro Kashitani, Minato-ku, Tokyo, Toyota Tsusho), is expected to contribute to the realization of a pipeline transportation model for hydrogen that could be implemented globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005285/en/

According to a paper published by the International Renewable Energy Agency , “Hydrogen has emerged as an important part of the clean energy mix needed to ensure a sustainable future.” However, the large-scale, stable transportation of hydrogen through new pipeline infrastructure faces issues including land acquisition construction costs and building time. Utilizing existing pipeline infrastructure can solve these issues, and this new study represents the next step in this model’s proof-of-concept process.

The study will examine a double-piping system in which a hydrogen pipeline is placed in an existing pipe (the “sheath pipe”) buried underground. Factors to be measured and contributed to the formulation of technical standards include:

  1. On-site investigation of hydrogen leakage detection
  2. Verification of detection of signs of abnormality
  3. Establishment of a control sequence to ensure safety
  4. Performance evaluation of various hydrogen sensors in a real-world environment

Safety measures will be investigated under the assumption of unsteady conditions including rupture accidents and natural disasters during pipeline operation. In addition to examining the safety measures necessary for such use of existing pipelines, the study will verify the profitability of such projects, including cost analysis of transportation; energy input; and economic efficiency, as compared to other hydrogen transportation means.

Based on the knowledge and data gained through this project, NTT Anode Energy and its collaborators will promote and establish technical studies on safety measures for practical use. Ultimately, the project will also support the future supply of hydrogen to urban areas (e.g., public and commercial facilities, data centers and communications buildings; fuel cell vehicles; hydrogen stations, etc.), supply through pipelines utilizing communication pipelines (e.g., cable tunnels) and will contribute to the development of smart cities and the establishment of hydrogen supply means through pipelines in regions with a view to a society that consumes a large amount of hydrogen through the development of CO2-free hydrogen.

This project is being conducted in accordance with the "Research and development for the full-scale popularization of ultra-high pressure hydrogen infrastructure/Research and development for international development, international standardization, etc./Research and study for the examination of technical standards for hydrogen supply infrastructure, etc." of the New Energy and Industrial Technology Development Organization .

Primary Areas of Research by Collaborator

NTT Anode Energy

  • Hydrogen leakage detection;
  • Abnormal sign detection;
  • Hydrogen sensors investigation;
  • Investigation of residual hydrogen concentration at the time of hydrogen leakage; and
  • Investigation of explosion effect of manhole cover

AIST

  • Investigation of fire flame behavior caused by the ignition of leaked hydrogen in a simulated double piping system

Toyota Tsusho

  • Clarification of unit costs through verification of equipment, installation and safety costs; and
  • Verification of advantageous conditions and business establishment requirements of pipeline transportation

About NTT Anode Energy Group

As a company focused on leveraging the information communications technology and DC power supply technologies of the NTT Group in pursuit of “smart energy” business opportunities, NTT Anode Energy is working to develop and deliver energy solutions that make more sophisticated and efficient use of distributed energy resources such as renewable power generation facilities and storage batteries. In this way, it can fully express the unique synergies of the NTT Group. Through these efforts, we aim to work with partner companies to create new energy distribution mechanisms to help to revitalize industries and shape a more sustainable society.

NTT and the NTT logo are registered trademarks or trademarks of NIPPON TELEGRAPH AND TELEPHONE CORPORATION and/or its affiliates. All other referenced product names are trademarks of their respective owners. © 2022 NIPPON TELEGRAPH AND TELEPHONE CORPORATION

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye